How much funding has StratifAI raised?

StratifAI has raised $15.4M in total funding, most recently a Seed round.

Who are StratifAI's investors?

StratifAI's investors include Picus Capital, Alven, Debiopharm Innovation, Heliad Equity Partners, Arve Capital.

Where is StratifAI headquartered?

StratifAI is headquartered in Berlin, Germany.

What industry is StratifAI in?

StratifAI operates in Artificial Intelligence, Biotech, Healthcare.

StratifAI

The AI biomarker company for precision oncology

Berlin, Germany · Founded 2023 · $15.4M raised

Artificial Intelligence

Biotech

Healthcare

Headquarters: Berlin
Employees: 11–50
Founded: 2023
Business Model: B2B

Website: stratifai.com
Total Funding: $15.4M
Last Round: $13.8M SeedSep 2025
Rounds: 2

About

StratifAI is a precision oncology company developing next-generation AI biomarkers to advance cancer diagnostics. Its flagship platform, Polaris, seamlessly integrates histology, RNASeq, and patient outcomes at scale to create a unified view of spatial biology that enables novel cancer biology discoveries. Polaris Breast, its first diagnostic product, assesses metastatic risk in early breast cancer directly from digitized histology slides, validated on more than 6,000 patients. The company has raised approximately 12.5M EUR in a round led by Picus Capital and is undergoing regulatory approval in both the EU and US. StratifAI is a member of the MSK iHub Challenge Cohort and has presented clinical data at ASCO 2026. Founded in 2023 and headquartered in Germany.

Summary

StratifAI is an Artificial Intelligence company based in Berlin, Germany, founded in 2023. It has raised $15.4M in total across 2 rounds, most recently a $13.8M Seed round in Sep 2025. Investors include Picus Capital, Alven and Debiopharm Innovation.